BBOT News & Events

"In the first quarter, we reported meaningful progress across all three clinical programs, including encouraging preliminary antitumor activity and a potentially differentiated safety profile for BBO-8520 in lung cancer; anti-tumor activity and a partial response (PR) in pancreatic cancer with BBO-11818 as monotherapy; and confirmation of full target engagement without hyperglycemia for BBO-10203," said Pedro J. Beltran, PhD, Chief Executive Officer of BBOT. "In addition, we announced the publication of BBO-11818 in Cancer Discovery, highlighting its role as a potent and selective pan-KRAS inhibitor. These results and our cash runway into 2028 position us well as we continue advancing our differentiated pipeline to provide new treatment options for patients with limited choices."

BridgeBio Oncology announced the appointment of Pedro Beltran as CEO and Idan Elmelech as COO effective April 20. This transition reflects BridgeBio Oncology entering a new phase of development as the company's three clinical assets enter expansions and combinations across multiple RAS-driven cancers. Beltran joined BridgeBio Pharma in 2020 as senior VP of biology and became chief scientific officer of BridgeBio Oncology in July 2023.